programmed death-1 receptor
<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>
17
A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction
11
Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients
9
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma
5
Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives
11
CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma
10
Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes
10
PD 1 tempers Tregs in chronic HCV infection
5
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
6
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
6
Immunotherapies: The Blockade of Inhibitory Signals
11
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
9
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor
10
CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment
15
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
11
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
8
<p>Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study</p>
14
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
25
Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
13
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
11